title: Octreotide for hypoglycemia caused by sulfonylurea and DPP-4 inhibitor.
abstract: We describe a type 2 diabetes patient with persistent hypoglycemia caused by sulfonylurea misuse on top of a DPP-4 inhibitor. Hyperinsulinemia was exaggerated by dextrose administration, but was successfully treated with octreotide. Since many patients are currently treated with DPP-4 inhibitors, the importance of octreotide has been increasing. For refractory sulfonylurea-induced hypoglycemia, especially when the patient is also being given an incretin-based therapy, octreotide should be considered.
authors.affiliation: Division of Diabetes and Metabolic Diseases, Nihon University School of Medicine, Itabashi, Tokyo 173-8610, Japan. Electronic address: yamaguchi.suguru@nihon-u.ac.jp.
authors.forename: Suguru
authors.initials: S
authors.lastname: Yamaguchi
authors.affiliation: Division of Diabetes and Metabolic Diseases, Nihon University School of Medicine, Itabashi, Tokyo 173-8610, Japan.
authors.forename: Midori
authors.initials: M
authors.lastname: Ikejima
authors.affiliation: Division of Diabetes and Metabolic Diseases, Nihon University School of Medicine, Itabashi, Tokyo 173-8610, Japan.
authors.forename: Asami
authors.initials: A
authors.lastname: Furukawa
authors.affiliation: Division of Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine, Itabashi, Tokyo 173-8610, Japan.
authors.forename: Masanori
authors.initials: M
authors.lastname: Abe
authors.affiliation: Division of Diabetes and Metabolic Diseases, Nihon University School of Medicine, Itabashi, Tokyo 173-8610, Japan.
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Nakazaki
authors.affiliation: Division of Diabetes and Metabolic Diseases, Nihon University School of Medicine, Itabashi, Tokyo 173-8610, Japan.
authors.forename: Hisamitsu
authors.initials: H
authors.lastname: Ishihara
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000009:adverse effects; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D004791:Enzyme Inhibitors; D005765:Gastrointestinal Agents; D013453:Sulfonylurea Compounds; D015282:Octreotide
keywords: DPP-4 inhibitor; Hypoglycemia; Octreotide; Sulfonylurea